Sort
4,870 grants matching “glp 1”
Develop a novel strategy to deliver N-acetylcysteine for AD treatment
$499,441Peisheng Xu · Acepre, Llc · R41 · FY2024 · AG
Scale-up and Synthesis of a Tau Oligomer Inhibitor to initiate IND enabling studies for AD and ADRD
$499,433James G. Moe · Oligomerix, Inc · R44 · FY2018 · AG
Minimally Invasive Intercostal Nerve Block Device to Treat Severe Pain and Reduce Usage of Opiates
$499,325Changfeng Tai · Thermaquil, Inc. · R41 · FY2019 · NS
Phase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome [IND 121109 acknowledged 8/27/14]
$499,311Eric Hollander · Albert Einstein College Of Medicine · R01 · FY2020 · FD
A PROOF-OF-CONCEPT CLINICAL TRIAL OF XENIN-25 IN THE TREATMENT OF TYPE 2 DIABETES
$499,036Burton M Wice · Washington University · RC1 · FY2010 · DK
Development of Novel Compounds for Treatment of Heart Arrhythmias in CPVT
$498,962Douglas J Kawahara · Elex Biotech, Llc · SB1 · FY2020 · HL
Continuation of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study
$498,960John M Lachin · George Washington University · U01 · FY2018 · DK
Comprehensive Analysis, Surveillance, and Statistics Initiative for Diabetes in the Young (CASSIDY)
$498,891Annemarie Gregory Hirsch · Geisinger Clinic · U18 · FY2025 · DP
CTN - Evaluation of SeMaglutide as an Adjunct to buprenorphine treatment for the treatment of opioid use disorder: A pragmatic Randomized placebo-controlled Trial (SMART)
$498,507T John Winhusen · University Of Cincinnati · UG1 · FY2024 · DA
Cerebral Spinal Fluid Shunt System with Dual Lumen Distal Catheter Redundancy to Minimize Revision Surgery
$498,034Tom Viker · Cerovations, Llc · R43 · FY2019 · NS
Surgical amelioration of type 2 diabetes: Hormones, microbiota and mitochondria
$498,007Peter J Havel · University Of California At Davis · RC1 · FY2010 · DK
Changes in CSF Biomarkers after Bariatric Surgery
$497,960Sharon L. Wardlaw · Columbia University Health Sciences · R01 · FY2023 · DK
Changes in CSF Biomarkers after Bariatric Surgery
$497,960Sharon L. Wardlaw · Columbia University Health Sciences · R01 · FY2021 · DK
Changes in CSF Biomarkers after Bariatric Surgery
$497,960Sharon L. Wardlaw · Columbia University Health Sciences · R01 · FY2022 · DK
PET Imaging of Damaging Neuroinflammation in Alzheimer's Disease
$497,602Andrew Christian Larson · Einsenca Inc. · R44 · FY2022 · AG
Long term change of GLP-1 insulinotropic effect after GBP surgery
$497,409Blandine B Laferrere · Columbia University Health Sciences · R01 · FY2014 · DK
Dual-action drug coated balloon to mitigate neointimal hyperplasia and promote endothelialization.
$497,306Jennifer Sherwood · Endomimetics, Llc · R43 · FY2022 · HL
Individual and Group Career Development Program
$496,971Jennifer Snyder · University Of Maryland Baltimore · U54 · FY2009 · AI
Percutaneous deliverable biomaterial for treating myocardial infarction
$496,930Adam M Kinsey · Ventrix, Inc. · R43 · FY2011 · HL
Molecular Imaging Agent to Detect Thrombus
$496,849Valerie Humblet · Collagen Medical, Llc · R44 · FY2021 · HL
Developing Novel Ambroxol Analogs as Disease-Modifying Therapies for Alzheimer's Disease and Related Dementias
$496,600Robert Johnston · Zywie Llc · R43 · FY2025 · AG
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer
$496,381Gerardo Guillermo Mackenzie · University Of California At Davis · R01 · FY2024 · CA
TOWARD TRANSLATION OF NANFORMULATED PACLITAXEL-PLATINUM COMBINATION
$496,337Alexander V Kabanov · Univ Of North Carolina Chapel Hill · R01 · FY2023 · CA
Metabolism of islets of langerhans and hormone release
$496,114Franz M Matschinsky · University Of Pennsylvania · R01 · FY2010 · DK
Development of TP-217 as a highly efficacious, broad-spectrum antibiotic for the
$496,101Anne Kathleen Radcliff · Cubrc, Inc. · R01 · FY2015 · AI